Top Page
Rocket Doctor AI
(OTC:AIDR)
Rocket Doctor AI (AIDR) vs. iShares MSCI Canada ETF (EWC)
Rocket Doctor AI Business Overview & Revenue Model
Rocket Doctor AI Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.75K | 10.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 468.15K | 10.99K | 0.00 | -377.28K | -656.40K | -326.85K |
| EBITDA | -8.73M | -7.52M | -2.33M | 0.00 | 0.00 | 0.00 |
| Net Income | -8.75M | -7.55M | -3.72M | -3.80M | -13.86M | -2.91M |
Balance Sheet | ||||||
| Total Assets | 18.54M | 1.28M | 739.31K | 13.67K | 942.51K | 313.20K |
| Cash, Cash Equivalents and Short-Term Investments | 117.59K | 1.23M | 715.53K | 2.50K | 916.75K | 312.64K |
| Total Debt | 613.46K | 152.00K | 584.79K | 566.28K | 0.00 | 0.00 |
| Total Liabilities | 10.45M | 486.43K | 1.48M | 2.20M | 832.62K | 576.46K |
| Stockholders Equity | 8.09M | 792.77K | -738.05K | -2.19M | 109.90K | -263.26K |
Cash Flow | ||||||
| Free Cash Flow | -5.08M | -4.44M | -740.08K | -1.46M | -6.29M | -2.01M |
| Operating Cash Flow | -5.08M | -4.44M | -740.08K | -1.46M | -6.29M | -2.01M |
| Investing Cash Flow | -1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 5.60M | 4.97M | 1.45M | 540.62K | 6.94M | 1.86M |
Rocket Doctor AI Technical Analysis
Rocket Doctor AI Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$35.65M | -7.34 | ― | ― | -48.53% | -9.66% | |
48 Neutral | C$64.58M | -4.36 | -207.53% | ― | ― | 7.04% | |
45 Neutral | C$10.41M | -2.74 | ― | ― | 16.04% | -455.38% | |
44 Neutral | C$13.82M | -2.77 | ― | ― | ― | 48.94% | |
40 Underperform | C$10.16M | -1.24 | -1143.80% | ― | -64.23% | 18.42% |
Rocket Doctor AI Corporate Events
Rocket Doctor AI Inc. has launched a non-brokered private placement under Canada’s listed issuer financing exemption to raise a minimum of approximately $3 million through the sale of 4,285,715 units at $0.70 each, with each unit comprising one common share and a one-year warrant exercisable at $0.85. The financing, which may include finder’s fees and additional warrants, is expected to close around January 19, 2026, subject to minimum subscription and regulatory approvals, and the company plans to deploy the proceeds toward digital marketing and customer acquisition, operating and administrative costs, research and development, and general working capital, supporting its growth ambitions in AI-powered healthcare and expansion of its digital platform for physicians and patients.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.71 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI has partnered with the CAN Health Network and Health Cities to launch an AI-powered Clinical Decision Support System (CDSS) in Alberta. The initiative, set to begin in December 2025, will initially be implemented at four primary care sites, aiming to reduce intake time and improve diagnostic accuracy. This project addresses critical challenges in Alberta’s healthcare system, such as staffing shortages and limited access to care, by providing AI-driven tools to improve efficiency and patient access. The collaboration underscores Rocket Doctor AI’s commitment to modernizing healthcare through responsible AI innovation, with plans for a province-wide rollout in 2026.
Rocket Doctor AI Inc. has announced a change in its executive team, with Christopher Cherry stepping in as the Interim Chief Financial Officer, replacing David Worner. The company has also granted stock options and restricted share units to its executive officers, directors, and consultants, which are part of its share compensation plans. This move is part of Rocket Doctor AI’s strategy to strengthen its leadership and incentivize its team, potentially impacting its operational efficiency and market positioning.
Rocket Doctor AI Inc., through its digital health platform Rocket Doctor, has announced a strategic partnership with Toronto Metropolitan University (TMU) to enhance clinical education for medical learners in Canada. This collaboration aims to expand teaching capacity by connecting independent physicians with TMU’s medical school, facilitating clinical faculty appointments, and supporting learner observation and mentorship. The partnership is poised to strengthen Ontario’s healthcare workforce by integrating diverse care settings, including virtual care, and preparing future physicians to meet the evolving needs of the healthcare system.
Rocket Doctor AI reported strong momentum in Q3 2025, driven by its U.S. expansion, new payer contracts, and platform growth. The company achieved continued revenue growth despite seasonal challenges and improved its cash position with a successful capital raise. Notably, Rocket Doctor expanded its in-network reach to over 13 million U.S. members, positioning itself for accelerated growth in the U.S. market. The company also launched initiatives like the Healthy Aging Program and emergency department diversion in Canada, reflecting its commitment to addressing healthcare challenges.
Rocket Doctor AI has entered into a definitive agreement to acquire Alea Health Holdings Ltd., aiming to enhance its capabilities in AI-driven mental health solutions. The acquisition will integrate Alea’s advanced online therapy platform with Rocket Doctor AI’s Global Library of Medicine, expanding its mental health services and geographic reach, particularly into the Middle East. This move is expected to strengthen Rocket Doctor AI’s position in the healthtech industry by leveraging Alea’s expertise and presence in high-growth markets, while also enhancing its mental health and primary care integration.
Rocket Doctor AI Inc. has announced the appointment of four senior leaders to its U.S. operations as part of a strategic initiative to accelerate growth and expand its digital health platform across key states. This move aims to strengthen the company’s medical and commercial capabilities, enhance clinical operations, and support its expansion efforts, particularly in rural and underserved communities, thereby advancing its vision for a more equitable healthcare system.
Rocket Doctor AI Inc. has engaged Fundamental Research Corp. (FRC) to provide analyst coverage, including financial analysis and business operation insights, over an 18-month period. This collaboration aims to enhance Rocket Doctor AI’s visibility among institutional investors and strengthen its market positioning by leveraging FRC’s extensive research capabilities.
Rocket Doctor AI has expanded its U.S. coverage by becoming in-network with two leading national insurers, adding over 6.5 million members across California and New York. This expansion increases Rocket Doctor’s total in-network reach to more than 13 million members nationwide, enhancing its ability to deliver AI-powered, physician-led healthcare services. The new agreements include coverage for commercially insured members, Medicare Advantage, and Veteran Affairs, marking a significant step in providing equitable access to care for veterans. This development strengthens Rocket Doctor’s position in the healthcare market, advancing its mission to improve access, equity, and affordability through technology-driven healthcare.
Rocket Doctor AI Inc. has engaged FN Media Group to conduct a three-day news and media marketing campaign starting the week of October 20, 2025. This strategic move is aimed at enhancing the company’s visibility and market presence, leveraging FN Media’s expertise in digital media advertising. The engagement is expected to bolster Rocket Doctor AI’s positioning in the healthcare industry, potentially expanding its reach and impact on stakeholders by promoting its innovative AI-powered healthcare solutions.
Rocket Doctor AI’s subsidiary, Treatment.com Inc., in collaboration with Rush River Research, has been awarded a $2 million NIH SBIR Phase II grant to advance an AI-powered family medical history tool. This project aims to improve early diagnosis and preventive care, particularly for African-American communities, by integrating cultural perspectives and community input into AI systems, thereby enhancing the accuracy and accessibility of healthcare solutions.